Jan ter Meulen | Chair of Research
Virometix AG

Dr. Jan ter Meulen, MD PhD, is a biotech executive with broad experience in vaccines for infectious disease and cancer, recombinant antibodies, and cell therapy. Dr. ter Meulen has more than 30 years of operational and strategic research experience in pharmaceutical, biotechnology and academic settings, including Head of Vaccine Basic Research at Merck & Co., Executive Director at Crucell NV, and CSO at Immune Design and Obsidian Therapeutics. He held academic appointments at the German Cancer Research Center Heidelberg, the Bernhard-Nocht Institute for Tropical Medicine Hamburg, and the Philipps-University Marburg . Dr. ter Meulen was an International Research Scholar of the Howard Hughes Medical Institute and a consultant for scientific agencies in the US, UK, Germany, France, South Africa and the European Commission.